OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

Miles Wang, a prominent researcher from OpenAI, is reportedly in advanced talks to launch a new AI-driven drug discovery startup with a valuation of $2 billion. This move signals a significant shift in the life sciences industry, where AI is poised to revolutionize drug development by accelerating the discovery process. The potential success of this startup could attract further investment in AI applications across various sectors of healthcare, highlighting a growing trend in leveraging artificial intelligence for scientific breakthroughs. This could lead to faster, more efficient drug development and ultimately, more affordable and accessible medications.